• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    8/7/25 12:50:20 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CCCC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    C4 Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    12529R107

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,749,421.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,750,383.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,750,383.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.7 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    C4 Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
    Item 2. 
    (a)Name of person filing:

    Morgan Stanley
    (b)Address or principal business office or, if none, residence:

    1585 Broadway, New York, NY 10036
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    12529R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    6.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Christopher O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:08/07/2025
    Get the next $CCCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCCC

    DatePrice TargetRatingAnalyst
    9/4/2025$8.00Buy
    Guggenheim
    12/19/2024$8.00 → $12.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$4.00Equal-Weight
    Stephens
    1/29/2024$6.00Underweight → Neutral
    JP Morgan
    12/13/2023$2.00 → $12.00Hold → Buy
    Stifel
    2/24/2023$12.00 → $10.00Underperform → Neutral
    Credit Suisse
    2/24/2023$15.00 → $5.00Neutral → Underweight
    JP Morgan
    11/4/2022$22.00 → $15.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on C4 Therapeutics with a new price target

    Guggenheim initiated coverage of C4 Therapeutics with a rating of Buy and set a new price target of $8.00

    9/4/25 9:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded C4 Therapeutics from Equal Weight to Overweight and set a new price target of $12.00 from $8.00 previously

    12/19/24 7:32:29 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens initiated coverage on C4 Therapeutics with a new price target

    Stephens initiated coverage of C4 Therapeutics with a rating of Equal-Weight and set a new price target of $4.00

    11/18/24 8:38:35 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Medical Officer Reyno Leonard converted options into 15,325 shares and covered exercise/tax liability with 7,382 shares, increasing direct ownership by 5% to 166,382 units (SEC Form 4)

    4/A - C4 Therapeutics, Inc. (0001662579) (Issuer)

    7/15/25 9:00:15 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Reyno Leonard covered exercise/tax liability with 7,382 shares, decreasing direct ownership by 4% to 166,382 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    7/14/25 4:19:30 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Anderson Kenneth Carl was granted 7,616 shares, increasing direct ownership by 6% to 135,225 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    7/2/25 4:17:16 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    8/7/25 12:50:20 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by C4 Therapeutics Inc.

    10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)

    8/7/25 7:11:58 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    8/7/25 7:04:42 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

    WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeutic use in patients with autoimmune diseases. "We are thrilled to see Biogen quickly advance the IRAK4 degrader that resulted from our collaboration toward the clinic in the hopes this molecule may bring a new treatment option to patients with autoimmune dise

    9/4/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada. IMS Annual Meeting 2025 Oral PresentationTitle: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaPresen

    9/3/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada. IMS Annual Meeting 2025 Oral PresentationTitle: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaPresen

    9/3/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

    Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended

    2/27/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

    In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin's Lymphoma, Cemsidomide Monotherapy Demonstrated a 38 Percent ORR and 19 Percent Complete Metabolic Response (CMR) Rate Across All Subtypes; In Peripheral T-Cell Lymphoma (PTCL), Cemsidomide Achieved a 44 Percent ORR and 25 Perc

    12/8/24 12:30:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 4:05:17 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Financials

    Live finance-specific insights

    View All

    C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

    – Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative to Approved and Investigational IKZF1/3 Degraders – – On-Target Dose Limiting Toxicity Observed; Modeling Suggests Differentiated Activity and PK Profile Provides Pathway to Increase Therapeutic Index with Alternative Dosing Schedule – – Company to Host Conference Call and Webcast Today at 2 pm ET – WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical co

    4/8/22 1:00:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

    - Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentations – - Conference Call and Webcast Scheduled for April 8, 2022, at 2 PM ET– WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will pr

    3/8/22 4:30:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care